I-Paxlovid: esikwaziyo ngephilisi le-Pfizer's Covid-19

I-Pfizer ifuna ukugunyazwa ukusetshenziswa okuphuthumayo kwa-FDA ngephilisi layo le-Covid-19 elithi Paxlovid.
Yabelana ngesihloko

Ezithendeni zokugunyazwa kweMerck antiviral molnupiravir's UK, uPfizer usezimisele ngokuzitholela elakhe iphilisi le-Covid-19, iPaxlovid, emakethe.Kuleli sonto, umenzi wezidakamizwa wase-US ufune ukugunyazwa ukusetshenziswa okuphuthumayo kwa-US Food and Drug Administration (FDA) kumuntu osanda kungena e-antiviral kubantu abane-Covid-19 emaphakathi kuya kokuphakathi, abasengozini enkulu yokulaliswa esibhedlela noma yokushona. waqala inqubo yokufuna imvume yokulawula kwamanye amazwe ahlanganisa i-UK, Australia, New Zealand kanye neNingizimu Korea, futhi uhlela ukufaka izicelo ezengeziwe.Isebenza kanjani i-Paxlovid?I-Paxlovid iyinhlanganisela ye-Pfizer's researchal antiviral PF-07321332 kanye nesilinganiso esiphansi i-ritonavir, umuthi wezidambisigciwane ojwayele ukusetshenziselwa ukwelapha i-HIV.Ukwelashwa kuphazamisa ukuphindaphinda kwe-SARS-CoV-2 emzimbeni ngokubophezela ku-3CL-like protease, i-enzyme ebalulekile ekusebenzeni kwegciwane nasekukhiqizeni kabusha.
Ngokokuhlaziywa kwesikhashana, uPaxlovid wehlise ubungozi bokulaliswa esibhedlela okuhlobene ne-Covid-19 noma ukufa ngama-89% kulabo abathole ukwelashwa zingakapheli izinsuku ezintathu izimpawu ziqale.Umuthi watholakala uphumelela kakhulu - i-1% kuphela yeziguli ezathola i-Paxlovid elaliswa esibhedlela ngosuku lwama-28 uma kuqhathaniswa no-6.7% wabahlanganyeli be-placebo-ukuthi ukuhlolwa kwaso kweSigaba II/III kwaqedwa kusenesikhathi futhi ukuhanjiswa okusemthethweni ku-FDA kwafakwa ngokushesha kunokuba kulindeleke.Ngaphezu kwalokho, ngenkathi kubikwe ukufa kwe-10 engalweni ye-placebo, akukho okwenzeka phakathi kwabahlanganyeli abathola i-Paxlovid.Njenge-molnupiravir, i-Paxlovid inikezwa ngomlomo, okusho ukuthi iziguli ze-Covid-19 zingaphuza umuthi ekhaya ekuqaleni kokutheleleka.Ithemba ukuthi ama-antiviral amasha afana nalawo avela eMerck nasePfizer azovumela abantu abane-coronavirus ethambile noma elinganiselayo ukuthi belashwe ngokushesha, kuvimbele ukuqhubekela phambili kwezifo futhi basize ukugwema ukukhungatheka ezibhedlela.

Ukuncintisana kwezidakamizwa ze-Covid-19 i-molnupiravir kaMerck, iphilisi lokuqala eligunyazwe i-Covid-19, kuthiwa lingashintsha umdlalo kusukela ucwaningo lwathola ukuthi lehlise ukulaliswa esibhedlela kanye nobungozi bokushona cishe ngama-50%.Kepha lokho akusho ukuthi umnikelo we-Pfizer we-antiviral ngeke ube nomphetho emakethe.Ukuhlaziywa kwesikhashana kokusebenza kwe-molnupiravir kuyathembisa, kodwa ukwehliswa kwengozi okumangazayo okubikwe yi-Pfizer kukhombisa ukuthi iphilisi layo lingafakazela isikhali esibalulekile enqolobaneni yohulumeni yokulwa nalolu bhubhane. imbangi ye-antiviral.Abanye ochwepheshe bazwakalise ukukhathazeka ngokuthi indlela ye-molnupiravir yokwenza ngokumelene ne-Covid-19 - ukulingisa ama-molecule e-RNA ukuze ibangele ukuguqulwa kwegciwane - ingase futhi yethule ukuguqulwa okuyingozi ku-DNA yomuntu.I-Paxlovid, uhlobo oluhlukile lwe-antiviral eyaziwa ngokuthi i-protease inhibitor, ayizange ibonise izimpawu "zokusebenzisana kwe-mutagenic DNA", kusho uPfizer.